Cell Therapy Using Adipose-Derived Stem Cells for Chronic Liver Injury in Mice
Authors: Ohashi, Kazuo; Matsubara, Yoshinori; Tatsumi, Kohei; Kohori, Ayako; Utoh, Rie; Kakidachi, Hiroshi; Horii, Akihiro; Tsutsumi, Masahiro; Okano, Teruo
Source: Cell Medicine, Volume 3, Numbers 1-3, January 2012 , pp. 113-119(7)
Publisher: Cognizant Communication Corporation
Abstract:The present study investigated whether transplantation of autologous adipose-derived stem cells (ASCs) administered into the systemic circulation of a mouse with chronic liver injury provides therapeutic efficacy in the absence of any undesirable side effects. The ASCs used were isolated from mice with the same genetic background as the recipient mice and expanded in vitro. For the induction of chronic liver injury, mice were repetitively administered twice a week with CCl4, a well-known hepatotoxin, for a period of 4 weeks. One day after the eighth dose of CCl4, ASC transplantation was performed by tail vein injection and subsequently followed by two additional doses of CCl4 administration. The recipient mice were divided into four groups (vehicle control, 1.5×103, 1.5×104, and 1.5×105 ASCs per mouse). One day after the final CCl4 administration, all mice were sacrificed to assess serum markers and liver histology. The level of serum markers for liver injury and hepatic function did not differ among the four groups. Similarly, no difference was observed in the liver histology between groups. Cell transplantation with ASCs in our model of chronic liver failure did not result in any observable side effects, but from our results, a single application of ASCs seems to be ineffective in improving liver injury.
Document Type: Research Article
Publication date: January 1, 2012
- The importance of translating original, peer-reviewed research and review articles on the subject of cell therapy and its application to human diseases to society has led to the formation of the journal Cell Medicine. To ensure high-quality contributions from all areas of transplantation, the same rigorous peer review will be applied to articles published in Cell Medicine. Articles may deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, and stem cells, among others. Basic clinical studies and immunological research papers may also be featured if they have a translational interest. To provide complete coverage of this revolutionary field, Cell Medicine will report on relevant technological advances and their potential for translational medicine. Cell Medicine will be a purely online Open Access journal. There will therefore be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow your work to be disseminated to a wider audience and also entitle you to a free PDF, as well as prepublication of an unedited version of your manuscript.